Jun 07, 2023 9:15 am EDT Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
May 11, 2023 4:01 pm EDT Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023 9:00 am EDT Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11
Apr 27, 2023 9:00 am EDT Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform
Mar 23, 2023 9:25 am EDT Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Mar 15, 2023 4:01 pm EDT Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 08, 2023 9:00 am EST Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
Mar 02, 2023 9:15 am EST Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award
Feb 16, 2023 9:25 am EST Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
Jan 25, 2023 8:00 am EST Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients